![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MARCO |
Gene summary for MARCO |
![]() |
Gene information | Species | Human | Gene symbol | MARCO | Gene ID | 8685 |
Gene name | macrophage receptor with collagenous structure | |
Gene Alias | SCARA2 | |
Cytomap | 2q14.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q4ZG40 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8685 | MARCO | C21 | Human | Oral cavity | OSCC | 1.31e-06 | 2.73e-01 | 0.2678 |
8685 | MARCO | C46 | Human | Oral cavity | OSCC | 1.22e-29 | 9.08e-01 | 0.1673 |
8685 | MARCO | LN46 | Human | Oral cavity | OSCC | 8.91e-32 | 1.27e+00 | 0.1666 |
8685 | MARCO | ATC2 | Human | Thyroid | ATC | 2.49e-06 | 8.52e-01 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
GO:00972424 | Oral cavity | OSCC | amyloid-beta clearance | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
GO:000689826 | Thyroid | ATC | receptor-mediated endocytosis | 118/6293 | 244/18723 | 1.17e-06 | 1.50e-05 | 118 |
GO:009724221 | Thyroid | ATC | amyloid-beta clearance | 23/6293 | 38/18723 | 6.05e-04 | 3.44e-03 | 23 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa04145113 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SCGB3A2 | MARCO | SCGB3A2_MARCO | UGRP1 | Lung | AAH |
SCGB3A2 | MARCO | SCGB3A2_MARCO | UGRP1 | Lung | AIS |
SCGB3A2 | MARCO | SCGB3A2_MARCO | UGRP1 | Lung | Healthy |
SCGB3A2 | MARCO | SCGB3A2_MARCO | UGRP1 | Lung | MIAC |
SCGB3A2 | MARCO | SCGB3A2_MARCO | UGRP1 | Lung | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MARCO | SNV | Missense_Mutation | c.274N>A | p.Pro92Thr | p.P92T | Q9UEW3 | protein_coding | tolerated(0.14) | benign(0.043) | TCGA-64-5778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Targeted Molecular therapy | tarceva | PD | |
MARCO | SNV | Missense_Mutation | c.275N>A | p.Pro92Gln | p.P92Q | Q9UEW3 | protein_coding | tolerated(0.16) | benign(0.023) | TCGA-64-5778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Targeted Molecular therapy | tarceva | PD | |
MARCO | SNV | Missense_Mutation | c.499N>T | p.Ala167Ser | p.A167S | Q9UEW3 | protein_coding | tolerated(0.57) | benign(0.042) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
MARCO | SNV | Missense_Mutation | c.1476N>T | p.Glu492Asp | p.E492D | Q9UEW3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
MARCO | SNV | Missense_Mutation | c.290N>A | p.Leu97Gln | p.L97Q | Q9UEW3 | protein_coding | deleterious(0.02) | benign(0.367) | TCGA-67-3770-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MARCO | SNV | Missense_Mutation | c.810N>A | p.Met270Ile | p.M270I | Q9UEW3 | protein_coding | tolerated(0.16) | benign(0.031) | TCGA-69-7764-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
MARCO | SNV | Missense_Mutation | novel | c.257T>C | p.Leu86Pro | p.L86P | Q9UEW3 | protein_coding | tolerated(0.08) | benign(0.046) | TCGA-86-7711-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | PD |
MARCO | SNV | Missense_Mutation | c.943G>C | p.Val315Leu | p.V315L | Q9UEW3 | protein_coding | deleterious(0.04) | benign(0.039) | TCGA-91-6829-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
MARCO | SNV | Missense_Mutation | c.457N>A | p.Pro153Thr | p.P153T | Q9UEW3 | protein_coding | deleterious(0.05) | benign(0.32) | TCGA-34-2604-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MARCO | SNV | Missense_Mutation | novel | c.454N>T | p.Ala152Ser | p.A152S | Q9UEW3 | protein_coding | tolerated(0.59) | benign(0.01) | TCGA-34-8455-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |